GILD - Mirum Pharmaceuticals IPO: At Phase 3 Of Development
With several licenses acquired from well-known pharmaceutical companies, Mirum Pharmaceuticals (MIRM) is a name to be followed carefully after the IPO. The most appealing is its pipeline. The company owns two product candidates at Phase 3 of development and several candidates at Phase 2 of development. The buying opportunity starts, in our opinion, at an enterprise value of $300 million. Competitors are trading with an enterprise value of more than $700 million, so the company could sell at this mark.
Source: Prospectus
Source: Prospectus
Business
Founded in 2018, Mirum Pharmaceuticals intends to develop